Objective. To assess cumulative survival rates and identify independent predictors of mortality in patients with incident systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) who had undergone routine screening for PAH at SSc centers in the US. Methods. The Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma registry is a prospective registry of SSc patients at high risk for PAH or with definite pulmonary hypertension diagnosed by right-sided heart catheterization within 6 months of enrollment. Only patients with World Health Organization group I PAH (mean pulmonary artery pressure >25 mm Hg and pulmonary capillary wedge pressure <15 mm Hg without significant interstitial lung disease) were included in these analyses. Results. In total, 131 SSc patients with incident PAH were followed for a mean ؎ SD of 2.0 ؎ 1.4 years. The 1-, 2-, and 3-year cumulative survival rates were 93%, 88%, and 75%, respectively. On multivariate analysis, age >60 years (hazard ratio [HR] 3.0, 95% confidence interval [95% CI] 1.1-8.4), male sex (HR 3.9, 95% CI 1.1-13.9), functional class (FC) IV status (HR 6.5, 95% CI 1.8 -22.8), and diffusing capacity for carbon monoxide (DLCO) <39% predicted (HR 4.2, 95% CI 1.3-13.8) were significant predictors of mortality. Conclusion. This is the largest study describing survival in patients with incident SSc-associated PAH followed up at multiple SSc centers in the US who had undergone routine screening for PAH. The survival rates were better than those reported in other recently described SSc-associated PAH cohorts. Severely reduced DLCO and FC IV status at the time of PAH diagnosis portended a poor prognosis in these patients.
Introduction
Pulmonary arterial hypertension (PAH) as confirmed by right-sided heart catheterization (RHC) affects 8 -12% of patients with systemic sclerosis (SSc; scleroderma) (1, 2) and is associated with a Ͼ3-fold increased risk of death compared with SSc patients without PAH (3, 4) . Compared to patients with idiopathic PAH and other forms of con-nective tissue disease (CTD)-associated PAH (5), patients with SSc-associated PAH experience poorer outcomes. Despite the availability of several PAH-specific therapies, recent studies of patients with incident SSc-associated PAH have estimated 1-and 3-year survival rates ranging from 72-86% and 39 -67%, respectively (1,3,6 -8) . Because several studies have indicated that early treatment of PAH can improve hemodynamics, exercise capacity, and survival (9 -11) , guidelines for the screening and early detection of PAH in SSc patients who are at high risk for PAH have been developed (12) . The Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry was established in 2006 to assess the outcomes of patients at high risk for developing PAH and of those with incident disease. The premise of the PHAROS registry is that early detection and close monitoring of PAH in SSc patients could improve healthrelated outcomes. Herein, we describe the cumulative survival rates and predictors of mortality in this cohort of patients with SSc-associated PAH followed up at specialized scleroderma centers throughout the US.
Patients and methods
The PHAROS registry is a longitudinal prospective registry involving 22 US scleroderma centers. The participating centers obtained institutional review board approval and all patients provided written informed consent prior to enrollment. The baseline characteristics and study design for the PHAROS registry have been described elsewhere (13) .
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Significance & Innovations
• The 1-, 2-, and 3-year cumulative survival rates were 93%, 88%, and 75%, respectively, in this multicenter US cohort of patients with incident systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) who had undergone routine screening for PAH.
• Severely decreased diffusing capacity for carbon monoxide and functional class IV status at the time of the PAH diagnosis portended a poor prognosis in SSc patients, particularly in older patients and in men.
cording to the 2009 Dana Point Classification Criteria for PH, with a mean PAP Ն25 mm Hg and pulmonary capillary wedge pressure Յ15 mm Hg on RHC without significant interstitial lung disease defined as an FVC Ն65% predicted and no or only mild fibrosis on a high-resolution computed tomography (HRCT) scan of the chest, were included in this analysis. The pre-PH patients could be recategorized as having definite PH based on RHC over the course of the study, and these patients were included in this analysis. A subgroup analysis of patients who received Ն3 continuous months of the same PAH-specific therapies over the first year of followup was performed. For this subgroup analysis, patients were divided into 4 different treatment categories based on the following initial PAH-specific therapy used as determined by the treating physicians: 1) endothelin receptor antagonist (ERA) monotherapy, 2) phosphodiesterase 5 (PDE-5) inhibitor monotherapy, 3) prostacyclin analogue (PCA) monotherapy, or 4) combination therapy with at least 2 PAH-specific therapeutic classes.
The following information was collected at baseline and on annual followup: demographics, medications, physical examination findings, New York Heart Association (NYHA) functional class (FC) assessment, serum autoantibodies, brain natriuretic peptide (BNP)/N-terminal proBNP levels if available, PFT results, TTE results, findings on HRCT, 6-minute walk distance (6MWD), and hemodynamics on RHC if performed. The primary outcome measure was death and the causes of death were recorded if known.
For statistical analysis, baseline characteristics were assessed by descriptive statistics. Kaplan-Meier curves were estimated for survival from the time of the first RHC at which PAH was confirmed. The differences in outcomes between subgroups were assessed by the log rank test. Cox regression models were used to identify significant predictors of mortality. DLCO, mean PAP, and pulmonary vascular resistance (PVR) were evaluated as categorical variables using the median value as the cut point. Demographic variables and those with a P value less than 0.1 in the univariate analyses were included in a multivariate model. Backward selection was used to determine the final model, retaining only variables with a P value less than 0.05.
For the analysis evaluating the effect of PAH-specific therapies on outcomes, Kaplan-Meier curves were estimated for 1-year survival from the time PAH-specific medication(s) were started, with differences between the treatment categories assessed by the log rank test.
Results
Baseline characteristics. Of the 434 patients enrolled in the PHAROS registry at the time of this analysis, 131 had incident PAH as determined by RHC during the study, 14 of whom developed RHC-proven PAH after enrollment into the registry (Table 1) . At the PAH diagnosis, the mean Ϯ SD age was 60.4 Ϯ 10.4 years and the mean Ϯ SD disease duration from the first Raynaud's phenomenon and first non-Raynaud's phenomenon symptoms was 14.4 Ϯ 12.0 and 10.3 Ϯ 9.2 years, respectively. The majority of patients were women (84%), were white (82%), and had limited cutaneous disease (70%). Approximately onethird of the patients were anticentromere antibody positive, 7% were Scl-70 positive, 6% had an anti-U1 RNP antibody, 4% were RNA polymerase III positive, 24% had an antinuclear antibody (ANA) with an isolated nucleolar pattern without other scleroderma-specific antibodies, 22% had a positive ANA alone without a nucleolar pattern 
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or other scleroderma-specific antibodies, and 5% were negative for all autoantibodies. Only 2.3% of patients had a creatinine level Ͼ2 mg/dl at the time of RHC, and the median creatinine level was 0.9 mg/dl. 
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More than half of the patients were classified as having NYHA FC I (18%) or II (37%) status at the time of RHC, while only 5% of the patients were classified as having FC IV status. The mean Ϯ SD RVSP on TTE was 61 Ϯ 20 mm Hg, and 39.6% of the patients had a pericardial effusion. On baseline pulmonary evaluation, the mean Ϯ SD DLCO was 42% Ϯ 16% predicted and the mean Ϯ SD 6MWD was 339 Ϯ 130 meters. Half of the patients had a baseline DLCO Ͻ40% predicted, while only 11% of the patients had severely compromised exercise capacity, defined as a 6MWD Ͻ165 meters. The baseline hemodynamics were relatively mild, with a mean Ϯ SD PAP of 36.5 Ϯ 10.3 mm Hg (median 35), mean Ϯ SD PVR of 5.6 Ϯ 3.4 Wood units (WUs; median 4.6), and mean Ϯ SD cardiac output of 5.0 Ϯ 1.5 liters/minute.
Survival. In total, 24 patients (18%) died over a mean Ϯ SD followup time of 2.0 Ϯ 1.4 years (median 2.0 years [range 0 -5.9 years]); 20 deaths (83%) were directly attributable to PAH or multiorgan failure related to underlying PAH. Other causes of death included new-onset scleroderma renal crisis (2 patients), infection (1 patient), and cancer (1 patient). The 1-, 2-, and 3-year survival rates in the overall SSc-associated PAH cohort were 93%, 88%, and 75%, respectively ( Figure 1A) .
Predictors of mortality.
The univariate regression analysis identified FC IV status (hazard ratio [HR] 6.0, 95% confidence interval [95% CI] 2.0 -18.2), DLCO Ͻ39% predicted (HR 4.3, 95% CI 1.6 -11.9), and PVR Ͼ4.6 WUs (HR 3.4, 95% CI 1.3-8.7) as significant predictors of mortality (Table 2 and Figures 1B and C) . On multivariate analysis, FC IV status (HR 6.5, 95% CI 1.8 -22.8) and DLCO Ͻ39% predicted (HR 4.2, 95% CI 1.3-13.8) remained significant, while age Ͼ60 years (HR 3.0, 95% CI 1.1-8.4) and male sex (HR 3.9, 95% CI 1.1-13.9) were also independent predictors of mortality.
Effect of PAH-specific therapies on survival.
Of the overall SSc-associated PAH cohort, 101 patients had received Ն3 continuous months of their initial PAH-specific therapies and Ն1 year of followup. The initial PAH treatment categories were as follows: ERA in 30%, PDE-5 in 48%, PCA in 13% (85% inhaled and 15% parenteral), and combination therapy in 10% of patients. Patients in the PCA group had a significantly lower mean Ϯ SD DLCO at 29% Ϯ 11% predicted compared with 45% Ϯ 18%, 42% Ϯ 14%, and 35% Ϯ 11% in the PDE-5, ERA, and combination therapy groups (P ϭ 0.03), respectively. Patients in the PCA group also had worse hemodynamics at the time of PH therapy initiation. The PCA group had a higher median mean PAP of 45 mm Hg (interquartile range [IQR] 40 -45) compared with 35 mm Hg (IQR 29 -40) in the PDE-5 group, 30 mm Hg (IQR 27-38) in the ERA group, and 38 mm Hg (IQR 33-53) in the combination therapy group (P ϭ 0.0008). PCA patients also had a significantly higher mean Ϯ SD PVR of 7.0 Ϯ 2.8 WUs, compared with 4.8 Ϯ 2.7 WUs for PDE-5, 3.7 Ϯ 2.1 WUs for ERA, and 6.9 Ϯ 2.1 WUs for combination therapy patients (P ϭ 0.0004). The prostacyclin-treated patients clearly had worse hemodynamics, suggesting a sicker population. At 1 year, 7 patients (7%) who were receiving PAH-specific therapies died. The 1-year survival rate was significantly worse in the PCA group (69%) compared with the other treatment categories (ERA 97%, PDE-5 98%, and combination therapy 90%; P ϭ 0.002).
Discussion
Our study described the outcomes of a large US SScassociated PAH cohort of incident patients who had close (1,3,6 -8) . We recognize that a direct comparison of survival rates between the PHAROS registry and other cohorts is not possible; however, our cohort was enriched in patients with less severe disease (56% of patients with FC I and II status versus 23% in REVEAL), which was likely due to screening and early detection of PAH. In total, 17% of deaths were unrelated to PAH, highlighting that other comorbid conditions influenced outcome in SSc-associated PAH patients. Our results concur with other smaller studies following early detection algorithms. Hachulla et al found 1-and 3-year survival rates of 100% and 80%, respectively, in 12 patients with SSc-associated PAH who were classified as having NYHA FC II status at diagnosis (10) . Similarly, Humbert et al compared survival rates in 16 patients with SSc-associated PAH diagnosed in routine practice with 16 patients diagnosed following a systematic PAH detection program, with 1-, 3-, 5-, and 8-year survival rates of 75%, 31%, 25%, and 17%, respectively, in the former group compared with 100%, 81%, 73%, and 64%, respectively, in the early detection group (11) . A recent Australian study of 117 patients with CTD-associated PAH had 1-and 3-year survival rates similar to ours (94% and 73%, respectively) (14) . Although the latter cohort primarily comprised patients with SSc-associated PAH, better outcomes were observed in non-SSc patients with CTD-associated PAH (5, 8) , which may have skewed the results.
On multivariate analysis, we found that older age, male sex, NYHA FC IV status, and low DLCO were independent predictors of mortality. Similarly, Condliffe et al found that younger age, female sex, and a lower NYHA FC were protective in patients with SSc-associated PAH (8) . A DLCO Ͻ39% predicted at PAH diagnosis was associated with a Ͼ4-fold increased risk of death in our cohort. Chandra et al found that a DLCO Ͻ43% predicted was associated with a lower HR of 2.4 (95% CI 1.1-5.0) in a cohort of 408 patients with WHO group I PAH, including 142 patients with CTD-associated PAH, but the number of SSc-associated PAH patients was not reported (15) . Our results emphasize the importance of monitoring DLCO for both PAH screening and prognostic purposes in patients with SSc. Unlike other PAH studies, we did not find an increased risk of death associated with the presence of a pericardial effusion, NYHA FC III status, or low 6MWD, which may reflect the effect of multisystem disease manifestations in SSc on these variables.
The patients started on PCA as initial therapy had the poorest survival of all treatment groups, but this was likely confounded by more severe disease at baseline. Given the short length of followup, it is difficult to make definitive conclusions regarding treatment outcomes, and additional followup data are being collected.
We recognize that there are limitations to this study. Although our study was a prospective multicenter cohort, it was observational and therefore missing data were inevitable, particularly data on BNP/N-terminal proBNP levels. We also did not collect information on mean right atrial pressure, an important predictor of mortality in other SScassociated PAH studies (1, 14) . Lead-time bias may have contributed to the improved survival rates observed in this population of patients with SSc-associated PAH who were diagnosed earlier with less severe disease due to existing PAH screening programs. Finally, PAH therapies were determined by the individual treating physicians, and not in a randomized controlled fashion.
Our study provided further evidence that early detection and management of PAH in SSc patients may lead to improved outcomes. Severely decreased DLCO and FC IV status at the time of PAH diagnosis portend a poor prognosis in SSc patients, particularly in older patients and men.
